Potential Biomarkers in Diagnosis of Human Gastric Cancer

References

• Emadi BM, Nikpour P, Emadi AE. SIX1 overexpression in diffuse type and grade III gastric tumors: features that are associated with poor prognosis. Adv Biomed Res 2015;4:139.
   PubMedGoogle Scholar
• Quéro L, Guillerm S, Hennequin C. Neoadjuvant or adjuvant therapy for gastric cancer. World J Gastrointest Oncol 2015;7(8):102–110.
   PubMedGoogle Scholar
• Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci 2010;14:302–308.
   PubMed Web of Science ®Google Scholar
• Tang P, Huang H, Chang J., Zhao GF, Liang M, Wang LY, et al. Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma. World J Gastroenterol 2013;19(17):2697–2703.
   PubMed Web of Science ®Google Scholar
• Aldemir MN, Turkeli M, Simsek M, Yildirim N, Bilen Y, Yetimoglu H, et al. Prognostic value of baseline neutrophil-lymphocyte and platelet-lymphocyte ratios in local and advanced gastric cancer patients. Asian Pac J Cancer Prev 2015;16(14):5933–5937.
   PubMedGoogle Scholar
• Barooei R, Mahmoudian RA, Abbaszadegan MR, Mansouri A, Gholamin M. Evaluation of thymic stromal lymphopoietin (TSLP) and its correlation with lymphatic metastasis in human gastric cancer. Med Oncol 2015;32:217.
   PubMed Web of Science ®Google Scholar
• Kim ST, Jang HL, Lee J, Park SH, Park YS, Lim HY, et al. Clinical significance of IGFBP-3 methylation in patients with early stage gastric cancer. Transl Oncol 2015;8(4):288–294.
   PubMed Web of Science ®Google Scholar
• Sapari NS, Loh M, Vaithilingam A, Soong, R. Clinical potential of DNA methylation in gastric cancer: a meta-analysis. PLoS One 2012;7:e36275.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Zhang S, Zhao P, Zeng HM, Zou XN, et al. Report of cancer incidence and mortality in China, 2010. Ann Transl Med 2014;2(7):61.
   PubMedGoogle Scholar
• Hanai A, Tsukuma H, Hiyama T. Survival of patients with stomach cancer: results from population-based cancer registries. In Gastric Cancer, T. Sugimura, and M. Sasako (eds.). New York: Oxford Univ. Press, 1997, 22–30.
   Google Scholar
• Martinez MR, Calvo, A. Patterns of failure and long-term results in high-risk resected gastric cancer treated with postoperative radiotherapy with or without intraoperative electron boos. J Surg Oncol 1997 Sep;66(1):24–29.
   PubMed Web of Science ®Google Scholar
• Lee CM, Cho JM, Jang YJ, Park SS, Park SH, Kin SJ, et al. Should lymph node micrometastasis be considered in node staging for gastric cancer?: the significance of lymph node micrometastasis in gastric cancer. Ann Surg Oncol 2015;22(3):765–771.
   PubMed Web of Science ®Google Scholar
• Yang J, Huang J, Yang Y, Fan N, Zhang X, Wang S, et al. Confocal laser endoscopy in the diagnosis for abdominal lymph node metastasis of gastric cancer. Int J Clin Exp Med 2015;8(6):8905–8915.
   PubMed Web of Science ®Google Scholar
• Oh SJ, Suh BJ. Metachronous liver metastasis resulting from early gastric carcinoma after subtotal gastrectomy following endoscopic resection: a case report. J Gastric Cancer 2015;15(2):139–142.
   PubMedGoogle Scholar
• Eiji O, Shoji T, Yasunori E, Yamamoto M, Fukuzawa K, Takahashi I, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer 2015; 1–9. doi: 10.1007/s10120-015-0530-z.
   Google Scholar
• Hisashi S, Shinsho M, Masaru K, Akiko M, Toyooki S, Pastan I. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J Surg Res 2002;102:169–177.
   PubMed Web of Science ®Google Scholar
• Ma H, Gao L, Li S, Qin J, Chen L, Liu X, et al. CCR7 enhances TGF-β1 induced epithelial- mesenchymal transition and is associated with lymph node metastasis and poor overall survival in gastric cancer. Oncotarget 2015; 6(27):4484.
   Google Scholar
• Bacalbaşa, N, Bălescu I, Calin M, Balalau C. Intraoperative radiation therapy in gastric cancer. J Med Life 2014;7(2):128–131.
   PubMedGoogle Scholar
• Pang, QQ, Ge JX, Shao YF, Sun WL, Song HJ, Xia T, et al. Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. Tumor Biol 2014;35:5441–5447.
   PubMed Web of Science ®Google Scholar
• He CZ, Zhang, KH. Serum protein and genetic tumor markers of gastric carcinoma. Asian Pac J Cancer Prev 2013;14:3437–3442.
   PubMedGoogle Scholar
• Tsai MM, Wang CS, Tsai CY, Chi HC, Tseng YH, Lin KH, et al. Potential prognostic, diagnostic and therapeutic markers for human gastric cancer. World J Gastroenterol 2014;20(38):13791–13803.
   PubMed Web of Science ®Google Scholar
• Rahden BH, Kircher S, Lazariotou M, Reiber C, Stuermer L, Otto C, et al. LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus? J Exp Clin Cancer Res 2011;30:23.
   PubMed Web of Science ®Google Scholar
• Sellheyer K. Basal cell carcinoma: cell of origin, cancer stem cell hypothesis and stem cell markers. Br J Dermatol 2011;164(4):696–711.
   PubMed Web of Science ®Google Scholar
• Liu LL, Fu D, Ma Y, Shen XZ. The power and the promise of liver cancer stem cell markers. Stem Cells Dev 2011;20(12):2023–2030.
   PubMed Web of Science ®Google Scholar
• Han Y, Xue X, Jiang M, Guo X, Li P, Liu F, et al. LGR5, a relevant marker of cancer stem cells, indicates a poor prognosis in colorectal cancer patients: a meta-analysis. Clin Res Hepatol Gastroenterol 2015;39(2):267–273.
   PubMed Web of Science ®Google Scholar
• Wu, XS, Xi, HQ, Chen, L. Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol 2012;10:244.
   PubMed Web of Science ®Google Scholar
• Zheng ZX, Sun Y, Bu ZD, Zhang LH, Li ZY, Wu AW, et al. Intestinal stem cell marker LGR5 expression during gastric carcinogenesis. World J Gastroenterol 2013;19(46):8714–8721.
   PubMed Web of Science ®Google Scholar
• Effendi K, Yamazaki K, Fukuma M, Sakamoto M. Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) represents a typical Wnt/β-Catenin pathway-activated hepatocellular carcinoma. Liver Cancer 2014;3(3–4):451–457.
   PubMedGoogle Scholar
• He S, Zhou H, Zhu X, Hu S, Fei M, Wan D, et al. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance. Biomed Pharmacother 2014;68(5):507–513.
   PubMed Web of Science ®Google Scholar
• Van der Flier LG, Sabates BJ, Oving I, Andrea H, Mariagrazia DP, Marcello A, et al. The intestinal Wnt/TCF signature. Gastroenterology 2007;132:628–632.
   PubMed Web of Science ®Google Scholar
• Barker N, van Es JH, Kuipers J, Kujala P, Born MVD, Cozijnsen M, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003–1007.
   PubMed Web of Science ®Google Scholar
• Jang BG, Lee BL, Kim, WH. Distribution of LGR5+ cells and associated implications during the early stage of gastric tumorigenesis. Plos One 2013;8(12):82390.
   Web of Science ®Google Scholar
• Lee A, Woo J, Park H, Sung SH, Seoh JY, Lim WH, et al. The value of cytoplasmic Y-box-binding protein 1 as a prognostic marker for breast cancer in Korean. Breast Cancer 2015; 1–7. doi: 10.1007/s12282-015-0625-8.
   Google Scholar
• Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry–-Moscow 2011;76:1402–1433.
   PubMed Web of Science ®Google Scholar
• Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA 1988;85:7322–7326.
   PubMed Web of Science ®Google Scholar
• Kohno K, Izumi H, Uchiumi T, Mashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bio Essays 2003;25:691–698.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Shimajiri S, Han B, Izumi H, Hirano G, Kashiwagi E, et al. Y-box binding protein-1 is a novel molecular target for tumor vessels. Cancer Sci 2010;101(6):1367–1373.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang KY, Li Z, Liu YP, Izumi H, Yamada S, et al. Y-box binding protein 1 expression in gastric cancer subtypes and association with cancer neovasculature. Clin Transl Oncol 2015;17(2):152–159.
   PubMed Web of Science ®Google Scholar
• Tomohiro S, Hitoshi K, Yuichi M, Hiroki U, Kosuke W, Akihiko K, et al. Y-box binding protein-1 contributes to both HER2/ErbB2 cells expression and lapatinib sensitivity in human gastric cancer. Mol Cancer Ther 2013;12:737–746.
   PubMed Web of Science ®Google Scholar
• Lasham A, Samuel W, Cao H, Patel R, Mehta R , Stern JL, et al. YB-1, the E2F pathway, and regulation of tumor cell growth. J Nat Cancer Inst 2012;104:133–146.
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 2012;13:633–641.
   PubMed Web of Science ®Google Scholar
• Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi M, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010;11:136–146.
   PubMed Web of Science ®Google Scholar
• Cai H, Yuan Y, Guo TK, Wei X, Zhang YM. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol 2013;30(1):452.
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Cui L, Ye GL, Zheng T, Song HJ, Xia T, et al. Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumor Biol 2012;33:2349–2355.
   PubMed Web of Science ®Google Scholar
• Yu X, Luo L, Zhao XY, Wu YB, Yu SH, Liu Y. Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol 2013;30(1):365.
   PubMed Web of Science ®Google Scholar
• Chan SH, Wu CW, Li AY, Chi CW, Lin WC. miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res 2008;28:907–911.
   PubMed Web of Science ®Google Scholar
• Wu J, Li G, Wang Z, Yao Y, Chen R, Pu XY, et al. Circulating microRNA-21 is a potential diagnostic biomarker in gastric cancer. Disease Mark 2015;2015:435656.
   PubMed Web of Science ®Google Scholar
• Yamanaka S, Olaru AV, An F, Luvsanjav D, Jin Z, Agarwal R, et al. MicroRNA-21 inhibits Serpini1, a gene with novel tumor suppressive effects in gastric cancer. Digest Liver Dis 2012;44(7):589–596.
   Web of Science ®Google Scholar
• Wang S, Hossein SM, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Modern Pathol 2002;15(2):137–145.
   PubMed Web of Science ®Google Scholar
• Proshkina GM, Shilova ON, Ryabova AV, Stremovskiy OA, Deyev SM. A new anticancer toxin based on HER2/neu-specific DARP in and photoactive flavor protein miniSOG. Biochimie 2015;118:116–122. doi: 10.1016/j.biochi.2015.08.013.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001 Feb; 2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Kümler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 2014;40(2):259–270.
   PubMed Web of Science ®Google Scholar
• Su Y, Jiang Y, Sun S, Yin H, Shan M, Tao W, et al. Effects of HER2 genetic polymorphisms on its protein expression in breast cancer. Cancer Epidemiol 2015; 39(6):1123–1127. doi: 10.1016/j.canep.2015.08.011.
   Web of Science ®Google Scholar
• Ko BK, Lee SY, Lee YH, Hwang IS, Persson H, Rockberg J, et al. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer. Mol Oncol 2015;9(2):398–408.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Fuse N, Kuwata T, Nomura S, Kaneko K, Doi T, et al. Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. Jpn J Clin Oncol 2015;45(1):43–48.
   PubMed Web of Science ®Google Scholar
• Tafe LJ, Janjigian YY, Zaidinski M. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 2011;135:1460–1465.
   PubMed Web of Science ®Google Scholar
• Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y, et al. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol 2012;18(45):6577–6586.
   PubMed Web of Science ®Google Scholar
• He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, et al. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol 2013;19(14):2171–2178.
   PubMed Web of Science ®Google Scholar
• Rakhshani N, Kalantari E, Bakhti H, Sohrabi MR, Mehrazma M. Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray. Asian Pac J Cancer Prev 2014;15(18):7597–7602.
   PubMedGoogle Scholar
• Kutter C, Watt S, Stefflova K, Wilson MD, Goncalves A, Ponting CP, et al. Rapid turnover of long noncoding RNAs and the evolution of gene expression. PLoS Genet 2012;8(7):e1002841.
   PubMed Web of Science ®Google Scholar
• Maruyama R, Suzuki, H. Long noncoding RNA involvement in cancer. BMB Rep 2012;45(11):604–611.
   PubMed Web of Science ®Google Scholar
• Chen X, Sun J, Song Y, Gao P, Zhao JH, Huang XZ, et al. The novel long noncoding RNA AC138128.1 may be a predictive biomarker in gastric cancer. Med Oncol 2014;31(11):262.
   PubMed Web of Science ®Google Scholar
• Wapinski O, Chang, H.Y. Long noncoding RNAs and human disease. Trends Cell Biol 2011;21(6):354–361.
   PubMed Web of Science ®Google Scholar
• Ye N, Wang B, Quan ZF, Cao SJ, Wen XT, Huang Y, et al. Functional roles of long non-coding RNA in human breast cancer. Asian Pac J Cancer Prev 2014;15(15):5993–5997.
   PubMedGoogle Scholar
• Cao WJ, Wu HL, He BS, Zhang YS, Zhang ZY. Analysis of long non-coding RNA expression profiles in gastric cancer. World J Gastroenterol 2013;19(23):3658–3664.
   PubMed Web of Science ®Google Scholar
• Ding J, Li D, Gong MZ, Wang J, Huang X, Wu T, et al. Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. Oncol Targets Therapy 2014;7:1625–1630.
   PubMed Web of Science ®Google Scholar
• Joiner DM, Ke J, Zhong Z, Eric XH, Williams BO. Lrp5 and Lrp6 in development and disease. Trends Endocrin Metab 2013;24(1):31–39.
   PubMed Web of Science ®Google Scholar
• Giles RH, van Es JH, Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653(1):1–24.
   PubMed Web of Science ®Google Scholar
• Peyman B, Jessica S, Anna KO, Göran Å, Gunnar W. The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. Plos One 2009;4(1):e4243.
   PubMed Web of Science ®Google Scholar
• Gordon MD, Nusse, R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006;281(32):22429–22433.
   PubMed Web of Science ®Google Scholar
• Katoh M, Katoh, M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007; 13(14):4042–4045.
   PubMed Web of Science ®Google Scholar
• Polakis P. The many ways of Wnt in cancer. Curr Opin Genetics Dev 2007;17(1):45–51.
   PubMed Web of Science ®Google Scholar
• Liu X, Huang MZ, Chen ZY, Zhao XY, Wang CC, Peng W. LRP5 polymorphism—A potential predictor of the clinical outcome in advanced gastric cancer patients treated with EOF regimen. Chin J Cancer Res 2014;26(4):478–485.
   PubMed Web of Science ®Google Scholar
• Sun H, Liu Z, Li B, Dai J, Wang X. Effects of DLX2 overexpression on the osteogenic differentiation of MC3T3-E1 cells. Exp Ther Med 2015 Jun; 9(6):2173–2179.
   PubMed Web of Science ®Google Scholar
• Qu B, Liu O, Fang X, Zhang H, Wang Y, Quan H. Distal-less homeobox 2 promotes the osteogenic differentiation potential of stem cells from apical papilla. Cell Tissue Res 2014;357(1):133–143.
   PubMed Web of Science ®Google Scholar
• Yan ZH, Bao ZS, Yan W, Liu YW, Zhang CB, Wang HJ. Upregulation of DLX2 confers a poor prognosis in blioblastoma patients by inducing a proliferative phenotype. Curr Mol Med 2013;13(3):438–445.
   PubMed Web of Science ®Google Scholar
• Morini M, Astigiano S, Gitton Y, Emionite L, Mirisola V, Levi G, et al. Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231. BMC Cancer 2010;10:649.
   PubMed Web of Science ®Google Scholar
• Murcia BV, Esteban PF, Martínez HJ, Gruart A, Luján R, Delgado GJM, et al. Anosmin-1 over-expression regulates oligodendrocyte precursor cell proliferation, migration and myelin sheath thickness. Brain Struct Func 2015: 1–21. DOI: 10.1007/s00429-015-1016-9.
   Google Scholar
• García GD, Murcia BV, Esteban PF, Ortega F, Díaz D, Sánchez VI, et al. Anosmin-1 over-expression increases adult neurogenesis in the subventricular zone and neuroblast migration to the olfactory bulb. Brian Struct Func 2016; 221(1):239–260. doi: 10.1007/s00429-014-0904-8.
   Google Scholar
• Choy CT, Kim H, Lee JY, Williams DM, Palethorpe D, Fellows G. Anosmin-1 contributes to brain tumor malignancy through integrin signal pathways. Endocrine-Related Cancer 2013;21(1):85–99.
   PubMed Web of Science ®Google Scholar
• Choy C, Kim SH. Biological actions and interactions of anosmin-1. Front Horm Res 2010;39:78–93.
   PubMed Web of Science ®Google Scholar
• Ayari B, Soussi, Y.N. FGFR1 and anosmin-1 underlying genetically distinct forms of Kallmann syndrome are co-expressed and interact in olfactory bulbs. Dev Genes Evolution 2007;217(2):169–175.
   PubMed Web of Science ®Google Scholar
• Kanda M, Shimizu D, Fujii T, Sueoka S, Tanaka Y, Ezaka K. Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer 2016; 138(3):721–730. doi: 10.1002/ijc.29803.
   Web of Science ®Google Scholar
• Kanda M, Nomoto S, Oya H, Shimizu D, Takami H, Hibino S, et al. Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. J Exp Clin Cancer Res 2014;33:66.
   PubMed Web of Science ®Google Scholar
• Guan ZY, Zhang J, Song SH, Dai DQ. Promoter methylation and expression of TIMP3 gene in gastric cancer. Diagn Pathol 2013;8:110.
   PubMed Web of Science ®Google Scholar
• Eaton RM, Shallcross JA, Mael LE, Mears KS, Minkoff L, Scoville DJ. Selection of DNA aptamers for ovarian cancer biomarker HE4 using CE-SELEX and high-throughput sequencing. Anal Bioanal Chem 2015; 407(23):6965–6973. DOI 10.1007/s00216-015-8665-7.
   PubMed Web of Science ®Google Scholar
• Yang ZG, Barbara KH, Sean G, Frost CG, Estrela P. A novel immobilization strategy for electrochemical detection of cancer biomarkers: DNA-directed immobilization of aptamer sensors for sensitive detection of prostate specific antigens. Analyst 2015;140:2628–2633.
   PubMed Web of Science ®Google Scholar
• Timothy C, Sandy C, Kim YT, Lee JH. Rapid aptasensor capable of simply diagnosing prostate cancer. Biosens Bioelectron 2014;62:31–37.
   PubMed Web of Science ®Google Scholar
• Jo H, Her J, Ban, C. Dual aptamer-functionalized silica nanoparticles for the highly sensitive detection of breast cancer. Biosens Bioelectron 2015;71:129–136.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kang HJ, Jang H, Lee YJ, Lee YS, Ali BA. Simultaneous imaging of two different cancer biomarkers using aptamer-conjugated quantum dots. Sensors 2015;15:8595–8604.
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee EJ, Kang YY, Mok H. Multivalent aptamer–RNA based fluorescent probes for carrier-free detection of cellular microRNA-34a in mucin1-expressing cancer cells. Chem Commun 2015;51(43):9038–9041. DOI: 10.1039/c5cc02052b.
   Web of Science ®Google Scholar
• Ho LC, Wu WC, Chang CY, Hsieh HH, Lee CH, Chang HT. Aptamer-conjugated polymeric nanoparticles for the detection of cancer cells through “Turn-On” retro-self-quenched fluorescence. Anal Chem 2015;87:4925–4932.
   PubMed Web of Science ®Google Scholar